Supplemental material
Journal of Medical Economics
Volume 24, 2021 - Issue 1
Open access
2,814
Views
3
CrossRef citations to date
0
Altmetric
Oncology
The cost-effectiveness of glasdegib in combination with low-dose cytarabine, for the treatment of newly diagnosed acute myeloid leukemia in adult patients who are not eligible to receive intensive induction chemotherapy in Canada
Yannan Hua Ingress-Health, Rotterdam, the NetherlandsCorrespondence[email protected]
, Majed Charaanb Pfizer Canada Inc, Quebec, Canada
, Ilse van Oostruma Ingress-Health, Rotterdam, the Netherlands
, Bart Heega Ingress-Health, Rotterdam, the Netherlands
https://orcid.org/0000-0002-9226-3232
Timothy Bellc Pfizer Inc, New York, USA
Pages 150-161
|
Received 23 Oct 2020, Accepted 21 Dec 2020, Published online: 01 Feb 2021
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.